Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus GYNOREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus GYNOREST.
ETHINYL ESTRADIOL; ETONOGESTREL vs GYNOREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Category D/X
Category C
Progestin
Progestin